Never use anthracyclines with trastuzumab: It is time to reconsider the taboo

Breast Cancer Research and Treatment

Volumn 117, Issue 3, 2009, Pages 599-601

  Gianni, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; MULTIPLE CYCLE TREATMENT; NOTE; PRIORITY JOURNAL; TARGET CELL; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HEART; HUMANS;

EID: 70349579241     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0402-5     Document Type: Note

References (23)

1. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
2. A Seidman C Hudis MK Pierri S Shak V Paton M Ashby M Murphy SJ Stewart D Keefe 2002 Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 5 1215 1221 11870163 10.1200/JCO.20.5.1215 1:CAS:528: DC%2BD38XisVWmuro%3D (Pubitemid 34177427)
3. DB Sawyer C Zuppinger TA Miller, et al. 2002 Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1b and anti-erbB2. Potential mechanism for trastuzumab-induced cardiotoxicity Circulation 105 1551 1554 11927521 10.1161/01.CIR.0000013839. 41224.1C 1:CAS:528:DC%2BD38XjtlCmtLc%3D (Pubitemid 34297631)
4. X Peng B Chen CC Lim DB Sawyer 2005 The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine Mol Interv 5 3 163 171 15994456 10.1124/mi.5.3.6 1:CAS:528:DC%2BD2MXmvVakt78%3D (Pubitemid 41018273)
5. MS Ewer DurandJB VooletichMT, et al. 2005 Reversibility of trastuzumab-related cardiotoxicity: newinsights based on clinical course and response to medical treatment J Clin Oncol 23 7820 7826 16258084 10.1200/JCO.2005.13.300 1:CAS:528:DC%2BD2MXht1Cqs7bP (Pubitemid 46657379)
6. Slamon DJ, Mackey J, Robert N et al. (2007) Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. 30th San Antonio Breast Cancer Symposium, December 13-16 (abstract 13)
7. Stickeler E, Klar M, Watermann D, et al. (2009) Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in Her2/neu positive Metastatic Breast Cancer: A Multicenter Phase II Trial. Breast Cancer Res Treat (this issue)
8. D Rayson D Richel S Chia C Jackisch S van der Vegt T Suter 2008 Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann Oncol 19 9 1530 1539 18480068 10.1093/annonc/mdn292 1:STN:280:DC%2BD1crivFGjsg%3D%3D
9. Muss HB, Thor AD, Berry DA, et al. (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260-6. Erratum in: N Engl J Med 331(3):211
10. A Moliterni S Ménard P Valagussa, et al. 2003 HER2 overexpression and doxorubicin in adjuvant chemotherapy for respectable breast cancer J Clin Oncol 21 3 458 462 12560435 10.1200/JCO.2003.04.021 1:CAS:528: DC%2BD2cXpsVGrtLo%3D (Pubitemid 46606475)
11. A Gennari MP Sormani P Pronzato, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 1 14 20 18159072 1:CAS:528:DC%2BD1cXit1Cku7o%3D
12. McArthur HL, Tan LK, Patil S, et al. (2008) High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer. 31st San Antonio Breast Cancer Symposium, December 10-14 2008 (abstract 2023)
13. Bartlett JMS, Munro A, Dunn JA, et al. (2008) Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEAT adjuvant breast cancer trial. 31st San Antonio Breast Cancer Symposium, December 10-14 2008 (abstract 45)
14. G Bianchi J Albanell W Eiermann, et al. 2003 Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer Clin Cancer Res 9 5944 5951 14676119 1:CAS:528:DC%2BD3sXpsl2ls7g%3D
15. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. 31st San Antonio Breast Cancer Symposium, December 10-14 2008 (abstract 31)
16. AU Buzdar NK Ibrahim D Francis, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 15738535 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D (Pubitemid 46252462)
17. Untch M, Tjulandin S, Jonat W, et al. (2007) Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer. 30th San Antonio Breast Cancer Symposium, December 13-16 2007 (abstract 4058)
18. ® docetaxel ± capecitabine as neoadjuvant treatment of HER2 overexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Res Treat 106:2007 (suppl 1; abstract 5053)
19. S Chia M Clemons LA Martin, et al. 2006 Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: amulticenter phase II trial J Clin Oncol 24 2773 2778 16682726 10.1200/JCO.2005.03.8331 1:CAS:528:DC%2BD28XntV2hu7o%3D (Pubitemid 46630575)
20. A Wolff M Bonetti J Sparano, et al. 2003 Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group trial E3198 Proc Am Soc Clin Oncol 22 A70
21. E Andreopoulou D Gaiotti E Kim, et al. 2007 Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer Clin Breast Cancer 7 690 696 17919349 10.3816/CBC.2007.n.028 1:CAS:528: DC%2BD2sXhtVOrsbbI
22. M Theodoulou SM Campos G Batist, et al. 2002 TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis Proc Am Soc Clin Oncol 21 55a
23. J Cortes S DiCosimo MA Climent, et al. 2009 Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study Clin Cancer Res 15 1 307 314 19118059 10.1158/1078-0432.CCR-08-1113 1:CAS:528:DC%2BD1MXhs1eruw%3D%3D